Ronald J Hinklin - JoVE Visualize

Showing results (11-20 of 15) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 15 results.

Cancer Discovery|June 3, 2023

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted TherapyAlexander Drilon, Manish R Sharma, Melissa L Johnson, et al.

ACS Medicinal Chemistry Letters|January 8, 2019

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.

ACS Medicinal Chemistry Letters|December 18, 2014

C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase ActivatorsXiaohui Du, Ronald J Hinklin, Yumei Xiong, et al.

Journal of Medicinal Chemistry|April 7, 2020

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.

Journal of Medicinal Chemistry|August 1, 2024

Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial EfficacyQuinn A Bumpers, Robert W Pipal, Anna M Benz-Weeden, et al.

Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 15 results.

Cancer Discovery|June 3, 2023

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted TherapyAlexander Drilon, Manish R Sharma, Melissa L Johnson, et al.

ACS Medicinal Chemistry Letters|January 8, 2019

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.

ACS Medicinal Chemistry Letters|December 18, 2014

C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase ActivatorsXiaohui Du, Ronald J Hinklin, Yumei Xiong, et al.

Journal of Medicinal Chemistry|April 7, 2020

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.

Journal of Medicinal Chemistry|August 1, 2024

Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial EfficacyQuinn A Bumpers, Robert W Pipal, Anna M Benz-Weeden, et al.

Pageof 2